纳武利尤单抗治疗Child-Pugh B级晚期肝细胞癌的I/II期研究
这项I/II期多中心开放标签非对照研究纳入Child-Pugh B7-B8级晚期肝细胞癌患者,接受纳武利尤单抗240 mg每2周一次治疗。研究者评估的客观缓解率为12%(95% CI 5-25%),疾病控制率55%(95% CI 40-69%),中位缓解持续时间9.9个月(95% CI 9.7-9.9)。治疗相关不良事件发生率51%,安全性与其他Child-Pugh A级患者可比。
要点
- Child-Pugh B级晚期肝癌患者客观缓解率12%,疾病控制率55%
- 中位缓解持续时间9.9个月,治疗相关不良事件发生率51%
- 纳武利尤单抗在Child-Pugh B级患者中显示临床活性和可控安全性
核心结论
- 纳武利尤单抗在Child-Pugh B级晚期肝细胞癌患者中显示临床活性和良好安全性,毒性可控,可能适用于该人群。
研究设计与样本
- I/II期、开放标签、非对照、多中心试验(27个中心),纳入Child-Pugh B7-B8级晚期肝细胞癌患者,静脉给予纳武利尤单抗240 mg每2周一次直至不可接受毒性或疾病进展。
主要发现
- 研究者评估的客观缓解率为12%(95% CI 5-25%),6例患者缓解;疾病控制率55%(95% CI 40-69%)。
- 中位至缓解时间2.7个月(四分位距1.4-4.2),中位缓解持续时间9.9个月(95% CI 9.7-9.9)。
- 治疗相关不良事件报告于25例患者(51%),导致2例患者(4%)停药;最常见3/4级治疗相关不良事件为转氨酶升高(n=2)、淀粉酶升高(n=2)和天冬氨酸氨基转移酶升高(n=2)。
- 纳武利尤单抗的安全性与Child-Pugh A级晚期肝细胞癌患者相当。
临床怎么用
- 对于Child-Pugh B级晚期肝细胞癌患者,纳武利尤单抗可作为考虑的治疗选择之一,但需进一步研究评估其安全性和有效性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B liver function are often excluded from clinical trials. In previous studies, overall survival for these patients treated with sorafenib was ∼3-5 months; thus, new treatments are needed. Nivolumab, alone or in combination with ipilimumab, is conditionally approved in the United States to treat patients with aHCC who previously received sorafenib. We describe nivolumab monotherapy outcomes in patients with Child-Pugh B status. METHODS: This phase I/II, open-label, non-comparative, multicentre trial (27 centres) included patients with Child-Pugh B (B7-B8) aHCC. Patients received intravenous nivolumab 240 mg every 2 weeks until unacceptable toxicity or disease progression. Primary endpoints were objective response rate (ORR) by investigator assessment (using Response Evaluation Criteria in Solid Tumors v1.1) and duration of response. Safety was assessed using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. RESULTS: Twenty-five sorafenib-naive and 24 sorafenib-treated patients began treatment between November 2016 and October 2017 (median follow-up, 16.3 months). Investigator-assessed ORR was 12% (95% CI 5-25%) with 6 patients responding; disease control rate was 55% (95% CI 40-69%). Median time to response was 2.7 months (interquartile range, 1.4-4.2), and median duration of response was 9.9 months (95% CI 9.7-9.9). Treatment-related adverse events (TRAEs) were reported in 25 patients (51%) and led to discontinuation in 2 patients (4%). The most frequent grade 3/4 TRAEs were hypertransaminasemia (n = 2), amylase increase (n = 2), and aspartate aminotransferase increase (n = 2). The safety of nivolumab was comparable to that in patients with Child-Pugh A aHCC. CONCLUSIONS: Nivolumab showed clinical activity and favourable safety with manageable toxicities, suggesting it could be suitable for patients with Child-Pugh B aHCC. LAY SUMMARY: In patients with advanced hepatocellular carcinoma, almost all systemic therapies require very good liver function, i.e. Child-Pugh A status. The evidence from this study suggests that nivolumab shows clinical activity and an acceptable safety profile in patients with hepatocellular carcinoma with Child-Pugh B status who have mild to moderate impairment of liver function or liver decompensation that might rule out other therapies. Further studies are warranted to assess the safety and efficacy of nivolumab in this patient population. CLINICAL TRIAL NUMBER: NCT01658878.
引用
- Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. J Hepatol. 2021. PMID: 34051329. doi:10.1016/j.jhep.2021.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。